Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2017

View Archived Issues

Harpoon Therapeutics completes USD 45M series B financing

Phase Ib trial of TLD-1433 meets primary and secondary objectives for first 3 patients

PI3K inhibition shows promise for idiopathic pulmonary fibrosis in GSK-2126458 study

New mouse model of idiopathic pulmonary fibrosis presented

Sichuan Kelun-Biotech Biopharmaceutical divulges dipeptidyl peptidase 4 inhibitors

Shanghai Hansoh Biomedical and collaborator present NS5A HCV inhibitors

Bayer Pharma discovers MKNK1 inhibitors

TaiGen Biotechnology submits NDA for Taigexyn intravenous formulation in China

Heptares Therapeutics identifies muscarinic acetylcholine M1/M4 receptor agonists

Acerta Pharma presents tyrosine-protein kinase BTK inhibitors

Trial results support the use of VVZ-149 for postoperative pain

Biohaven finishes enrollment in study of trigriluzole in patients with spinocerebellar ataxia

FDA grants fast track designation for AMO-02 as treatment of congenital myotonic dystrophy

EMA grants PRIME designation for asunercept as treatment of glioblastoma

Molecular Partners gives additional details on clinical studies of MP-0250

Novel syndrome associated with first mutation identified in the KCTD15 gene

Dasiglucagon receives positive opinion for designation as orphan medicinal product

Array BioPharma and Bristol-Myers enter collaboration for binimetinib and nivolumab combination

Arcturus Therapeutics receives CFFT funding to advance the development of LUNAR-CF

Protagonist Therapeutics and Janssen enter into worldwide agreement for PTG-200

Health Canada grants approval for Resverlogix's clinical trial of apabetalone in Fabry disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...